AEON Biopharma is a biopharmaceutical company advancing ABP-450 as a BOTOX® biosimilar. Recent $6 million PIPE financing and note exchanges have reduced the company’s outstanding debt by over 90%.
Basic and diluted net loss per share (EPS) for 2025 was $(3.95), compared to a basic net income per share of $77.74 in 2024. The provided consolidated statements of operations do not report any revenue for either 2025 or 2024.
The company reported a 2025 net loss of $39.2 million, contrasting with a $42.0 million net income in 2024. Cash and cash equivalents totaled $3.0 million at year-end 2025.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.